Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Werewolf Therapeutics (HOWL) FCF Margin (2022 - 2024)

Werewolf Therapeutics (HOWL) has disclosed FCF Margin for 3 consecutive years, with 1241.82% as the latest value for Q2 2024.

  • Quarterly FCF Margin fell 110749.0% to 1241.82% in Q2 2024 from the year-ago period, while the trailing twelve-month figure was 5247.77% through Mar 2025, down 500850.0% year-over-year, with the annual reading at 2994.27% for FY2024, 282689.0% down from the prior year.
  • FCF Margin for Q2 2024 was 1241.82% at Werewolf Therapeutics, up from 2076.55% in the prior quarter.
  • The five-year high for FCF Margin was 15.24% in Q2 2022, with the low at 2076.55% in Q1 2024.
  • Average FCF Margin over 3 years is 514.24%, with a median of 223.5% recorded in 2023.
  • The sharpest move saw FCF Margin skyrocketed 13415bps in 2023, then tumbled -185305bps in 2024.
  • Over 3 years, FCF Margin stood at 208.35% in 2022, then tumbled by -65bps to 343.5% in 2023, then plummeted by -262bps to 1241.82% in 2024.
  • According to Business Quant data, FCF Margin over the past three periods came in at 1241.82%, 2076.55%, and 343.5% for Q2 2024, Q1 2024, and Q4 2023 respectively.